Supplementary Tables S1-S7 from Ancestral Differences in Anticancer Treatment Efficacy and Their Underlying Genomic and Molecular Alterations

Supplementary Table S1. The outcomes of all 46 clinical trials with racial comparisons. Supplementary Table S2. The list of clinically actionable genes. Supplementary Table S3. Summary of TCGA cancer types, patient samples and data types surveyed in this study. For each data type and each cancer type, the numbers of EUR, EAS and AFR patients available in the analysis are shown. NA: the data type in that cancer type was not included in the analysis. Cancer types are marked red for further analysis. Supplementary Table S4. Detailed information of independent mutation datasets Supplementary Table S5. Summary of TCGA cancer types with imputed drug data in this study. For each data type and each cancer type, the numbers of EUR, EAS and AFR patients available in the analysis are shown. NA: the data type in that cancer type was not included in the analysis. Cancer types are marked red for further analysis. Supplementary Table S6. FDA approved anti-cancer drugs during 1949 to 2023. Supplementary Table S7. Detailed information of independent cohorts.